OncoSil Medical Management
Management criteria checks 0/4
OncoSil Medical's CEO is Nigel Lange, appointed in Jan 2021, has a tenure of 4.83 years. total yearly compensation is A$923.46K, comprised of 49.8% salary and 50.2% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth A$4.50K. The average tenure of the management team and the board of directors is 0.5 years and 1.5 years respectively.
Key information
Nigel Lange
Chief executive officer
AU$923.5k
Total compensation
| CEO salary percentage | 49.76% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | less than a year |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | AU$923k | AU$459k | -AU$15m |
| Mar 31 2025 | n/a | n/a | -AU$14m |
| Dec 31 2024 | n/a | n/a | -AU$13m |
| Sep 30 2024 | n/a | n/a | -AU$12m |
| Jun 30 2024 | AU$745k | AU$476k | -AU$12m |
| Mar 31 2024 | n/a | n/a | -AU$12m |
| Dec 31 2023 | n/a | n/a | -AU$12m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$639k | AU$388k | -AU$11m |
| Mar 31 2023 | n/a | n/a | -AU$11m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$11m |
| Jun 30 2022 | AU$608k | AU$388k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$11m |
| Dec 31 2021 | n/a | n/a | -AU$11m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$964k | AU$359k | -AU$10m |
Compensation vs Market: Nigel's total compensation ($USD600.62K) is above average for companies of similar size in the Australian market ($USD294.89K).
Compensation vs Earnings: Nigel's compensation has increased whilst the company is unprofitable.
CEO
Nigel Lange
Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 4.8yrs | AU$923.46k | 0.020% A$ 4.5k | |
| Chief Financial Officer | less than a year | AU$280.48k | no data | |
| Head of Medical Affairs | 4.8yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
Experienced Management: OSL's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 4.8yrs | AU$923.46k | 0.020% A$ 4.5k | |
| Independent Non-Executive Chairman | less than a year | no data | no data | |
| Independent Non-Executive Director | 2.3yrs | AU$110.61k | 0.33% A$ 74.4k | |
| Independent Non-Executive Director | less than a year | AU$23.91k | no data |
Experienced Board: OSL's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 18:19 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoSil Medical Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity Historic (Wilsons Advisory and Stockbroking Ltd. |
| Thomas Duthy | Taylor Collison Limited |